What are the key life sciences trends to watch during the second half of 2025? Evolving regulations, precision medicine, and ...

Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about ...

Polymorphs, or different crystalline forms of the same drug, can be selected for distinct properties and patented. A recent ...

<p>On this week&#39;s episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real world impacts, among other things, can help, explains Bennett Smith.

Ocugen co-founder and CEO Shankar Musunuri, Ph.D. explains what biotech leaders can learn from the Philadelphia Eagles, an ...

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits of FDA breakthrough therapy designation, and talks about why RFK Jr. as HHS ...

In the world of biopharmaceutical innovation, groundbreaking scientific discoveries often do not directly translate into commercial success. Simply developing a promising therapeutic based on great ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

AI is becoming increasingly sophisticated, taking on responsibilities that were once exclusive to human beings. However, there are also disadvantages posed by ethical issues and the risk that AI may ...

By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL John Oyler Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with ...

In the increasingly complex world of artificial intelligence (AI), the concept of "correct outcomes" takes on a profound and sometimes ambiguous meaning. Although efforts are made to create AI that ...